Company Overview

For personal use only IHL-42X Obstructive Sleep Apnea Problem People suffering from OSA (Obstructive Sleep Apnea) have interrupted breathing while asleep. It's a highly prevalent condition and current treatments have poor patient compliance. There are no approved pharmacotherapies for OSA. Solution IHL-42X has two active pharmaceutical ingredients (Dronabinol and acetazolamide) that target OSA through different pathways. Dronabinol binds to cannabinoid receptors, modulates signalling, and activates muscles that dilate the airway whereas acetazolamide induces metabolic acidosis which signals to the body that there is excess CO₂ in the blood, inducing the taking of a breath. IHL-42X is intended to decrease the required dose of each of the component drugs by targeting the two mechanisms for reducing AHI simultaneously. Clinical development status Asset IHL-42X Obstructive Sleep Apnea* Incannex Preclinical Phase 2a CT FDA Pre-IND FDA IND Addressable Market US $10B Estimated sleep apnea device market FDA Phase 2 (1) FDA Phase 3 Lead Assets 0000000000 6.2% Annual Growth Rate * IHL-42X Australian clinical trial investigating safety and efficacy in OSA patients. (1) https://www.grandviewresearch.com/industry-analysis/sleep-apnea-devices-market Unblinded and confidential interim clinical data provided to the patent examiner. Patent application considered novel and inventive. Anticipated Milestones Open FDA IND Q4 2022 Commence IND opening clinical trial Investor Presentation 14

View entire presentation